The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)

Summary

This is a randomized, observer-blinded, active-controlled Phase I study to evaluate the safety, reactogenicity, and immunogenicity of REC610, when administered as 2 intramuscular (IM) injections in healthy adults aged 40 years and older, who do not have known HZ and history of varicella or HZ vaccination. The recombinant HZ vaccine, Shingrix® (GlaxoSmithKline), will be used as the active control.

Timeline

Start

2023-02-09

Primary completion

2023-12-06

Completion

2023-12-06

Drugs

Indications